Physician profile
Olga A Slepchenko
NPI 1538558960
$2,225.15
in general payments reported to CMS, 2019-2025
19 companies · $762 in 2025
The $762 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $394 · 2024: $1,069 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $316.14 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $282.92 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.59 | 2023-2025 | Caplyta |
| Abbvie INC. | $271.95 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $197.35 | 2023-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $173.73 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $157.37 | 2024-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $116.01 | 2024-2025 | Loreev Xr |
| Neos Therapeutics, LP | $82.76 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $58.24 | 2025 | Cobenfy |
| Tris Pharma INC | $52.69 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $51.33 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $49.02 | 2023-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $43.92 | 2024-2025 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $23.26 | 2023 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.89 | 2025 | |
| Idorsia Pharmaceuticals US INC | $20.20 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $19.85 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $12.93 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Slepchenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.